blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3167882

EP3167882 - USE OF FENOFIBRATE OR A DERIVATIVE THEREOF FOR PREVENTING DIABETIC RETINOPATHY [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  12.02.2021
Database last updated on 25.09.2024
FormerThe patent has been granted
Status updated on  06.03.2020
FormerGrant of patent is intended
Status updated on  29.10.2019
FormerRequest for examination was made
Status updated on  24.11.2017
FormerThe application has been published
Status updated on  18.04.2017
Most recent event   Tooltip10.06.2022Lapse of the patent in a contracting state
New state(s): CY		published on 13.07.2022  [2022/28]
Applicant(s)For all designated states
BGP Products Operations GmbH
Hegenheimermattweg 127
4123 Allschwil / CH
[2017/20]
Inventor(s)01 / ANSQUER, Jean-Claude
14 rue Clément Janin
F-21000 Dijon / FR
02 / KEECH, Anthony
29 Sofala Avenue
Riverview
Sydney, New South Wales / AU
 [2017/20]
Representative(s)FRKelly
Waterways House
Grand Canal Quay
Dublin D02 PD39 / IE
[N/P]
Former [2020/15]FRKelly
27 Clyde Road
Dublin D04 F838 / IE
Former [2017/20]O'Connell, Maura
FRKelly
27 Clyde Road
Dublin D04 F838 / IE
Application number, filing date16185410.410.11.2006
[2017/20]
Priority number, dateEP2005029238810.11.2005         Original published format: EP 05292388
[2017/20]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3167882
Date:17.05.2017
Language:EN
[2017/20]
Type: B1 Patent specification 
No.:EP3167882
Date:08.04.2020
Language:EN
[2020/15]
Search report(s)(Supplementary) European search report - dispatched on:EP31.03.2017
ClassificationIPC:A61K31/215, A61K31/216, A61K31/19, A61K31/192, A61P27/00
[2017/20]
CPC:
A61K31/19 (EP,KR,US); A61K31/215 (EP,KR,US); A61K31/192 (EP,US);
A61K31/216 (EP,KR,US); A61P27/00 (EP); A61P27/02 (EP);
A61P3/10 (EP) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2017/52]
Former [2017/20]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  NL,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
TitleGerman:VERWENDUNG VON FENOFIBRAT ODER EINEM DERIVAT DAVON ZUR PRÄVENTION VON DIABETISCHER RETINOPATHIE[2017/20]
English:USE OF FENOFIBRATE OR A DERIVATIVE THEREOF FOR PREVENTING DIABETIC RETINOPATHY[2017/20]
French:UTILISATION DU FÉNOFIBRATE OU L'UN DE SES DÉRIVÉS POUR LA PRÉVENTION DE LA RÉTINOPATHIE DIABÉTIQUE[2019/47]
Former [2017/20]UTILISATION DE FÉNOFIBRATE OU D'UN DE SES DÉRIVÉS POUR LA PRÉVENTION DE LA RÉTINOPATHIE DIABÉTIQUE
Examination procedure23.08.2016Date on which the examining division has become responsible
17.11.2017Amendment by applicant (claims and/or description)
17.11.2017Examination requested  [2017/52]
30.10.2019Communication of intention to grant the patent
25.02.2020Fee for grant paid
25.02.2020Fee for publishing/printing paid
25.02.2020Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP06829976.7  / EP1954261
Opposition(s)12.01.2021No opposition filed within time limit [2021/11]
Fees paidRenewal fee
10.02.2017Renewal fee patent year 03
10.02.2017Renewal fee patent year 04
10.02.2017Renewal fee patent year 05
10.02.2017Renewal fee patent year 06
10.02.2017Renewal fee patent year 07
10.02.2017Renewal fee patent year 08
10.02.2017Renewal fee patent year 09
10.02.2017Renewal fee patent year 10
28.11.2016Renewal fee patent year 11
23.03.2018Renewal fee patent year 12
13.11.2018Renewal fee patent year 13
28.11.2019Renewal fee patent year 14
Penalty fee
Additional fee for renewal fee
23.08.201603   M06   Fee paid on   10.02.2017
23.08.201604   M06   Fee paid on   10.02.2017
23.08.201605   M06   Fee paid on   10.02.2017
23.08.201606   M06   Fee paid on   10.02.2017
23.08.201607   M06   Fee paid on   10.02.2017
23.08.201608   M06   Fee paid on   10.02.2017
23.08.201609   M06   Fee paid on   10.02.2017
23.08.201610   M06   Fee paid on   10.02.2017
30.11.201712   M06   Fee paid on   23.03.2018
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT08.04.2020
CY08.04.2020
DK08.04.2020
EE08.04.2020
FI08.04.2020
LV08.04.2020
MC08.04.2020
SE08.04.2020
IS08.08.2020
[2022/28]
Former [2021/31]AT08.04.2020
DK08.04.2020
EE08.04.2020
FI08.04.2020
LV08.04.2020
MC08.04.2020
SE08.04.2020
IS08.08.2020
Former [2021/11]AT08.04.2020
DK08.04.2020
EE08.04.2020
FI08.04.2020
LV08.04.2020
SE08.04.2020
IS08.08.2020
Former [2021/08]DK08.04.2020
FI08.04.2020
LV08.04.2020
SE08.04.2020
IS08.08.2020
Former [2020/51]FI08.04.2020
LV08.04.2020
SE08.04.2020
IS08.08.2020
Former [2020/48]FI08.04.2020
SE08.04.2020
IS08.08.2020
Former [2020/46]IS08.08.2020
Documents cited:Search[XY]EP0482498  (SQUIBB & SONS INC [US]);
 [Y]WO02080936  (ORTHO MCNEIL PHARM INC [US]);
 [Y]EP1325745  (NISSAN CHEMICAL IND LTD [JP], et al);
 [Y]WO2004052362  (NOVARTIS AG [CH], et al);
 [Y]WO2004066963  (MERCK & CO INC [US], et al);
 [YD]US2005148594  (CINK RUSSELL D [US], et al);
 [Y]WO2005074909  (GRELAN PHARMACEUTICAL CO [JP], et al);
 [YP]EP1714648  (ASKA PHARM CO LTD [JP]);
by applicantWO8201649
 US4800079
 US4895726
 US4961890
 EP0793958
 US6042847
 US6074670
 WO0072825
 WO02067901
 US2005148594
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.